Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.